ISHARA INVESTMENTS LP
Q2 2026 Form 13-F
LOS ANGELES, DELAWARE
CIK 0002111609
· CRD 331869
· SEC-registered investment adviser
$136.1M Reported Value Total
ISHARA INVESTMENTS LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $259,118,831, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $19.9M gross asset value
Hedge Fund: $19.9M
Source: Form ADV filed 2026-03-19
Reported value
$136.1M
Quarter over quarter
+25.0%
Holdings
41
Top-10 concentration
51.0%
Key People
Form ADV owners & control persons
Shaun Ravi Mehra
FOUNDER, LIMITED PARTNER
Seth Ira Berman
CHIEF COMPLIANCE OFFICER/CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $136.1M |
| Positions | 41 |
| Change in reported value | +28.9% |
| New positions | 16 |
| Exited positions | 11 |
| Position turnover | 51.9% |
| Top-10 concentration | 51.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
41 | $136.1M |
|
Q1 2026 13F
Filed May 15, 2026
|
36 | $105.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
37 | $87.5M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACAD ACADIA PHARMACEUTICALS INC | $10.4M | 7.62% |
| 2 | XERS XERIS BIOPHARMA HOLDINGS INC | $9.7M | 7.16% |
| 3 | BMRN BIOMARIN PHARMACEUTICAL INC | $8.2M | 6.03% |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | $7.5M | 5.55% |
| 5 | RARE ULTRAGENYX PHARMACEUTICAL IN | $6.8M | 5.03% |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | $6.1M | 4.47% |
| 7 | INSM INSMED INC | $5.5M | 4.01% |
| 8 | CRNX CRINETICS PHARMACEUTICALS IN | $5.4M | 3.95% |
| 9 | ZNTL ZENTALIS PHARMACEUTICALS INC | $5.0M | 3.65% |
| 10 | PCVX VAXCYTE INC | $4.8M | 3.5% |
| 11 | ANNX ANNEXON INC | $4.7M | 3.44% |
| 12 | TVTX TRAVERE THERAPEUTICS INC | $4.7M | 3.42% |
| 13 | TNXP TONIX PHARMACEUTICALS HLDG C | $4.3M | 3.17% |
| 14 | BBIO BRIDGEBIO PHARMA INC | $4.3M | 3.14% |
| 15 | AXSM AXSOME THERAPEUTICS INC. | $4.0M | 2.95% |
| 16 | CTNM CONTINEUM THERAPEUTICS INC | $3.4M | 2.47% |
| 17 | LXRX LEXICON PHARMACEUTICALS INC | $3.1M | 2.24% |
| 18 | KURA KURA ONCOLOGY INC | $3.0M | 2.23% |
| 19 | DBVT DBV TECHNOLOGIES S A | $3.0M | 2.22% |
| 20 | GMAB GENMAB A/S | $2.8M | 2.07% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.